Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/7078
NATURALLY ACQUIRED ANTIBODIES TO PLASMODIUM VIVAX DUFFY BINDING PROTEIN (DBP) IN RURAL BRAZILIAN AMAZON.
Author
Affilliation
Fundação Oswaldo Cruz. Research Center René Rachou. Laboratory of Malaria. Belo Horizonte, MG, Brazil
Fundação Oswaldo Cruz. Research Center René Rachou. Laboratory of Malaria. Belo Horizonte, MG, Brazil
Fundação Oswaldo Cruz. Research Center René Rachou. Laboratory of Malaria. Belo Horizonte, MG, Brazil
Fundação Oswaldo Cruz. Research Center René Rachou. Laboratory of Malaria. Belo Horizonte, MG, Brazil
Fundação Oswaldo Cruz. Research Center René Rachou. Laboratory of Malaria. Belo Horizonte, MG, Brazil
University of São Paulo. Institute of Biomedical Sciences. Department of Parasitology. São Paulo, SP, Brazil
University of São Paulo. Institute of Biomedical Sciences. Department of Parasitology. São Paulo, SP, Brazil
Institute of Tropical Medicine of São Paulo. Laboratory of Protozoology. São Paulo, SP, Brazil
Fundação Oswaldo Cruz. Research Center René Rachou. Laboratory of Malaria. Belo Horizonte, MG, Brazil
Fundação Oswaldo Cruz. Research Center René Rachou. Laboratory of Malaria. Belo Horizonte, MG, Brazil
Fundação Oswaldo Cruz. Research Center René Rachou. Laboratory of Malaria. Belo Horizonte, MG, Brazil
Fundação Oswaldo Cruz. Research Center René Rachou. Laboratory of Malaria. Belo Horizonte, MG, Brazil
University of São Paulo. Institute of Biomedical Sciences. Department of Parasitology. São Paulo, SP, Brazil
University of São Paulo. Institute of Biomedical Sciences. Department of Parasitology. São Paulo, SP, Brazil
Institute of Tropical Medicine of São Paulo. Laboratory of Protozoology. São Paulo, SP, Brazil
Abstract
Duffy binding protein (DBP), a leading malaria vaccine candidate, plays a critical role in Plasmodium vivax erythrocyte invasion. Sixty-eight of 366 (18.6%) subjects had IgG anti-DBP antibodies by enzyme-linked immunosor bent assay (ELISA) in a community-based cross-sectional survey in the Brazilian Amazon Basin. Despite continuous exposure to low-level malaria transmission, the overall seroprevalence decreased to 9.0% when the population was reexamined 12 months later. Antibodies from 16 of 50 (36.0%) subjects who were ELISA-positive at the baseline were able to inhibit erythrocyte binding to at least one of two DBP variants tested. Most (13 of 16) of these subjects still had inhibitory anti-bodies when reevaluated 12 months later. Cumulative exposure to malaria was the strongest predictor of DBP seroposi-tivity identified by multiple logistic regression models in this population. The poor antibody recognition of DBP elicited by natural exposure to P. vivaxin Amazonian populations represents a challenge to be addressed by vaccine development strategies.
Share